NCT06282458Phase 2Completed

Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2025-04-11Actual

Enrollment · participants168Actual

Source updated2025-09-17Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Muscle Loss; Obesity

Treatments or interventions studied

EnobosarmDrug
SemaglutideDrugAlso known as Wegovy

Primary outcomes · main study measures

measure: The primary endpoint for the study is the percentage change from baseline in total lean body mass at 112 days.; description: To determine the effect of enobosarm on total lean mass as measured by DEXA in patients maintained on GLP-1 receptor agonists (percent change in total lean mass) at 112 days.; timeFrame: Day 112

History coverage

Imported research includes version dates later than the current official API record (2025-09-17). Disputed observations are retained for audit and excluded from trusted change feeds and sponsor statistics. Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history